ReviewJournal of medical genetics2018
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
Review in Journal of medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel.Molecular oncology · 2026Article
- Article
- Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.Breast cancer research and treatment · 2025Article
- Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma.JCO precision oncology · 2024Article
- Human-Centered Design Study to Inform Traceback Cascade Genetic Testing Programs at Three Integrated Health Systems.Public health genomics · 2023Article
- Article
- Practice guidelines forJournal of medical genetics · 2022Review
- Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.International journal of environmental research and public health · 2022Review
- An appraisal of genetic testing for prostate cancer susceptibility.NPJ precision oncology · 2022Review
- A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Current oncology (Toronto, Ont.) · 2022Article
- Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.BMC cancer · 2021Article
- Article
- Review
- Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.Molecular oncology · 2021Article
- Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.Cancer · 2020Article
- Review
- Response to Tomao, Panici, and Tomao.Journal of the National Cancer Institute · 2020Article
- Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.Journal of the National Cancer Institute · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.